Skip to main content

Advertisement

SpringerLink
Log in

In malignant cartilagenous tumors, immunohistochemical expression of procollagen PC1CP peptide is higher and that of PC2CP lower than in benign cartilaginous lesions

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Few studies on oncogenesis of chondrosarcoma (CS) are available in the literature. Our previously published experimental evidence suggests that while the C-propeptide of procollagen Iα1 (PC1CP), a component of cartilage, favors tumor progression, the C-propeptide of procollagen IIα1 (PC2CP) exerts antitumor properties. In this study, we analyzed expression of PC1CP and PC2CP by immunohistochemistry in a series of enchondromas and CS. Our retrospective series consisted of 88 cases, including 43 CSs, 34 enchondromas and 11 nontumor samples. Immunohistochemical staining for PC1CP and PC2CP was evaluated in the cytoplasm and in the extracellular matrix (ECM). Diffuse staining for PC1CP in ECM was significantly more frequent in tumor than in nontumor samples (32 % vs. 0 %; p = 0.03), and in CSs than in enchondromas (44 vs. 18 %; p = 0.02). ECM semiquantitative score was higher in tumors than in nontumor samples (p < 0.005) and higher in CSs than in enchondromas (p = 0.05). Staining for PC2CP in ECM was more frequently found in enchondromas than in CSs (59 vs. 33 %; p = 0.02). ECM semiquantitative score was higher in enchondromas than in CSs (p = 0.02). Diffuse staining for PC1CP in combination with absence of staining for PC2CP had 94 % specificity for CS but with a sensitivity of only 35 %. Expression of neither PC1CP nor PC2CP correlated with recurrence-free survival or occurrence of metastases. In conclusion, we show that the expression of PC1CP is higher and that of PC2CP lower in malignant cartilaginous tumors. These results support an oncogenic role of PC1CP and anti-oncogenic property of PC2CP in cartilaginous tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Fletcher CDM (2013) WHO classification of tumours of soft tissue and bone. IARC Press, Lyon

    Google Scholar 

  2. Eefting D, Schrage YM, Geirnaerdt MJ, Le Cessie S, Taminiau AH, Bovee JV, Hogendoorn PC (2009) Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol 33:50–57. doi:10.1097/PAS.0b013e31817eec2b

    Article  PubMed  Google Scholar 

  3. Aigner T (2002) Towards a new understanding and classification of chondrogenic neoplasias of the skeleton–biochemistry and cell biology of chondrosarcoma and its variants. Virchows Arch 441:219–230. doi:10.1007/s00428-002-0641-x

    Article  CAS  PubMed  Google Scholar 

  4. Bovee JV, Hogendoorn PC (2010) Molecular pathology of sarcomas: concepts and clinical implications. Virchows Arch 456:193–199. doi:10.1007/s00428-009-0828-5

    Article  PubMed Central  PubMed  Google Scholar 

  5. Bovee JV, Cleton-Jansen AM, Kuipers-Dijkshoorn NJ, van den Broek LJ, Taminiau AH, Cornelisse CJ, Hogendoorn PC (1999) Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Genes Chromosom Cancer 26:237–246

    Article  CAS  PubMed  Google Scholar 

  6. Hallor KH, Staaf J, Bovee JV, Hogendoorn PC, Cleton-Jansen AM, Knuutila S, Savola S, Niini T, Brosjo O, Bauer HC, Vult von Steyern F, Jonsson K, Skorpil M, Mandahl N, Mertens F (2009) Genomic profiling of chondrosarcoma: chromosomal patterns in central and peripheral tumors. Clin Cancer Res 15:2685–2694. doi:10.1158/1078-0432.CCR-08-2330

    Article  CAS  PubMed  Google Scholar 

  7. Sandberg AA (2004) Genetics of chondrosarcoma and related tumors. Curr Opin Oncol 16:342–354

    Article  PubMed  Google Scholar 

  8. de Andrea CE, Wiweger MI, Bovee JV, Romeo S, Hogendoorn PC (2012) Peripheral chondrosarcoma progression is associated with increased type X collagen and vascularisation. Virchows Arch 460:95–102. doi:10.1007/s00428-011-1168-9

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Aigner T, Dertinger S, Vornehm SI, Dudhia J, von der Mark K, Kirchner T (1997) Phenotypic diversity of neoplastic chondrocytes and extracellular matrix gene expression in cartilaginous neoplasms. Am J Pathol 150:2133–2141

    PubMed Central  CAS  PubMed  Google Scholar 

  10. Aigner T, Frischholz S, Dertinger S, Beier F, Girkontaite I, von der Mark K (1997) Type X collagen expression and hypertrophic differentiation in chondrogenic neoplasias. Histochem Cell Biol 107:435–440

    Article  CAS  PubMed  Google Scholar 

  11. Bovee JV, Cleton-Jansen AM, Wuyts W, Caethoven G, Taminiau AH, Bakker E, Van Hul W, Cornelisse CJ, Hogendoorn PC (1999) EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet 65:689–698. doi:10.1086/302532

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Schrage YM, Hameetman L, Szuhai K, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC, Bovee JV (2009) Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma. Am J Pathol 174:979–988. doi:10.2353/ajpath.2009.080623

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Aigner T, Muller S, Neureiter D, Illstrup DM, Kirchner T, Bjornsson J (2002) Prognostic relevance of cell biologic and biochemical features in conventional chondrosarcomas. Cancer 94:2273–2281. doi:10.1002/cncr.10461

    Article  PubMed  Google Scholar 

  14. Vincourt JB, Etienne S, Cottet J, Delaunay C, Malanda CB, Lionneton F, Sirveaux F, Netter P, Plenat F, Mainard D, Vignaud JM, Magdalou J (2010) C-propeptides of procollagens I alpha 1 and II that differentially accumulate in enchondromas versus chondrosarcomas regulate tumor cell survival and migration. Cancer Res 70:4739–4748. doi:10.1158/0008-5472.CAN-10-0046

    Article  CAS  PubMed  Google Scholar 

  15. Fang M, Yuan J, Peng C, Li Y (2014) Collagen as a double-edged sword in tumor progression. Tumour Biol 35:2871–2882. doi:10.1007/s13277-013-1511-7

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Pace JM, Wiese M, Drenguis AS, Kuznetsova N, Leikin S, Schwarze U, Chen D, Mooney SH, Unger S, Byers PH (2008) Defective C-propeptides of the proalpha2(I) chain of type I procollagen impede molecular assembly and result in osteogenesis imperfecta. J Biol Chem 283:16061–16067. doi:10.1074/jbc.M801982200

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Han S, Makareeva E, Kuznetsova NV, DeRidder AM, Sutter MB, Losert W, Phillips CL, Visse R, Nagase H, Leikin S (2010) Molecular mechanism of type I collagen homotrimer resistance to mammalian collagenases. J Biol Chem 285:22276–22281. doi:10.1074/jbc.M110.102079

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Makareeva E, Han S, Vera JC, Sackett DL, Holmbeck K, Phillips CL, Visse R, Nagase H, Leikin S (2010) Carcinomas contain a matrix metalloproteinase-resistant isoform of type I collagen exerting selective support to invasion. Cancer Res 70:4366–4374. doi:10.1158/0008-5472.CAN-09-4057

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Dornauer K, Soder S, Inwards CY, Bovee JV, Aigner T (2010) Matrix biochemistry and cell biology of dedifferentiated chondrosarcomas. Pathol Int 60:365–372. doi:10.1111/j.1440-1827.2010.02530.x

    Article  PubMed  Google Scholar 

  20. Tarpey PS, Behjati S, Cooke SL, Van Loo P, Wedge DC, Pillay N, Marshall J, O'Meara S, Davies H, Nik-Zainal S, Beare D, Butler A, Gamble J, Hardy C, Hinton J, Jia MM, Jayakumar A, Jones D, Latimer C, Maddison M, Martin S, McLaren S, Menzies A, Mudie L, Raine K, Teague JW, Tubio JM, Halai D, Tirabosco R, Amary F, Campbell PJ, Stratton MR, Flanagan AM, Futreal PA (2013) Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nat Genet 45:923–926. doi:10.1038/ng.2668

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Helfenstein A, Frahm SO, Krams M, Drescher W, Parwaresch R, Hassenpflug J (2004) Minichromosome maintenance protein (MCM6) in low-grade chondrosarcoma: distinction from enchondroma and identification of progressive tumors. Am J Clin Pathol 122:912–918. doi:10.1309/G638-TKNN-G2CJ-UXWL

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Elodie SPEYER (Epidemiology and Clinical Evaluation, CHU Nancy, France) for statistical analyses and all the team of the Department of Pathology (CHU Nancy) for technical support.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Pathology, CHU, Nancy, France

    Camille Delaunay-Lemarie, Béatrice Marie, Jean-Michel Vignaud & Guillaume Gauchotte

  2. UMR 7561 CNRS, Faculty of Medicine, Université de Lorraine, Vandoeuvre-lès-Nancy, France

    Jean-Baptiste Vincourt, Stéphanie Etienne & Jacques Magdalou

  3. Department of Biochemistry and Molecular Biology, CHU, Nancy, France

    Shyue-Fang Battaglia-Hsu

  4. INSERM U954, Faculty of Medicine, Université de Lorraine, Vandoeuvre-lès-Nancy, France

    Shyue-Fang Battaglia-Hsu, Jean-Michel Vignaud & Guillaume Gauchotte

  5. Department of Orthopedics, Centre Chirurgical Emile Gallé, Nancy, France

    François Sirveaux

  6. ESPRI - Clinical Epidemiology and Evaluation Department, CHU, Vandoeuvre-lès-Nancy, France

    Phi Linh Nguyen Thi

  7. Centre de Ressources Biologiques BB-0033-00035, CHU, Nancy, France

    Jean-Michel Vignaud

  8. Service d’Anatomie et Cytologie Pathologiques, Hôpital Central, CHU de Nancy, 29, avenue du Maréchal de Lattre de Tassigny, 54000, Nancy, France

    Guillaume Gauchotte

Authors
  1. Camille Delaunay-Lemarie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Baptiste Vincourt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Béatrice Marie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shyue-Fang Battaglia-Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stéphanie Etienne
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. François Sirveaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Phi Linh Nguyen Thi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jacques Magdalou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jean-Michel Vignaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Guillaume Gauchotte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guillaume Gauchotte.

Additional information

Jean-Michel Vignaud and Guillaume Gauchotte contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Delaunay-Lemarie, C., Vincourt, JB., Marie, B. et al. In malignant cartilagenous tumors, immunohistochemical expression of procollagen PC1CP peptide is higher and that of PC2CP lower than in benign cartilaginous lesions. Virchows Arch 467, 329–337 (2015). https://doi.org/10.1007/s00428-015-1799-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-015-1799-3

Keywords

Search

Navigation